The groundbreaking rise of Sildenafil presented a considerable opportunity for shareholders , but its exclusivity has lapsed , creating a complex landscape. Alternative versions have entered the space , cutting into revenues and putting a strain on profit margins . While leading drug companies continue a foothold in this field , the outlook seems c